{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:48:12Z","timestamp":1792507692625,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40487-026-00432-z","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T07:38:54Z","timestamp":1775374734000},"page":"499-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts"],"prefix":"10.1007","volume":"14","author":[{"given":"D\u00e9sir\u00e9e","family":"Deandreis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jacene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Therasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Haigis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,5]]},"reference":[{"issue":"4","key":"432_CR1","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.220157","volume":"5","author":"BJ Burkett","year":"2023","unstructured":"Burkett BJ, Bartlett DJ, McGarrah PW, et al. A review of theranostics: perspectives on emerging approaches and clinical advancements. Radiol Imaging Cancer. 2023;5(4):e220157.","journal-title":"Radiol Imaging Cancer"},{"issue":"5","key":"432_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2967\/jnumed.124.269215","volume":"66","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Scott AM, Abdlkadir AS, et al. Consensus nomenclature for radionuclide therapy: initial recommendations from nuclear medicine global initiative. J Nucl Med. 2025;66(5):757\u201363.","journal-title":"J Nucl Med"},{"issue":"8","key":"432_CR3","first-page":"817","volume":"19","author":"M Balma","year":"2023","unstructured":"Balma M, Liberini V, Buschiazzo A, et al. The role of theragnostics in breast cancer: a systematic review of the last 12\u00a0years. Curr Med Imaging. 2023;19(8):817\u201331.","journal-title":"Curr Med Imaging"},{"issue":"6","key":"432_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annonc.2023.03.001","volume":"34","author":"KL Pomykala","year":"2023","unstructured":"Pomykala KL, Hadaschik BA, Sartor O, et al. Next generation radiotheranostics promoting precision medicine. Ann Oncol. 2023;34(6):507\u201319.","journal-title":"Ann Oncol"},{"issue":"1","key":"432_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/acm2.13175","volume":"22","author":"FH Fahey","year":"2021","unstructured":"Fahey FH, Grant FD. Celebrating eighty years of radionuclide therapy and the work of Saul Hertz. J Appl Clin Med Phys. 2021;22(1):4\u201310.","journal-title":"J Appl Clin Med Phys"},{"issue":"4","key":"432_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2967\/jnumed.124.267524","volume":"65","author":"BS Greenspan","year":"2024","unstructured":"Greenspan BS, Hofman MS, Buscombe J. The accomplishments and legacy of Saul Hertz, MD. J Nucl Med. 2024;65(4):659\u201363.","journal-title":"J Nucl Med"},{"key":"432_CR7","doi-asserted-by":"crossref","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. Phase\u00a03 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u2013135.","DOI":"10.1056\/NEJMoa1607427"},{"issue":"12","key":"432_CR8","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase\u00a03 trial. Lancet Oncol. 2021;22(12):1752\u201363.","journal-title":"Lancet Oncol"},{"key":"432_CR9","doi-asserted-by":"crossref","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021; 385(12):1091\u2013103.","DOI":"10.1056\/NEJMoa2107322"},{"issue":"10459","key":"432_CR10","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase\u00a03, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339.","journal-title":"Lancet"},{"issue":"17","key":"432_CR11","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMc1803343","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378(17):1653\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"432_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025;22(1):26\u201345.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"432_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","volume":"4","author":"MK Bakht","year":"2023","unstructured":"Bakht MK, Yamada Y, Ku SY, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4(5):699\u2013715.","journal-title":"Nat Cancer"},{"key":"432_CR14","doi-asserted-by":"crossref","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase\u00a02 trial. Lancet Oncol. 2024; 25(1):99\u2013107.","DOI":"10.1016\/S1470-2045(23)00529-6"},{"issue":"1","key":"432_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2967\/jnumed.124.268167","volume":"66","author":"RA Demirci","year":"2025","unstructured":"Demirci RA, Ghodsi A, Gulati R, et al. PET-Based TheraP eligibility and outcomes of VISION-eligible patients with metastatic castration-resistant prostate cancer who received 177Lu-PSMA-617: Importance of 18F-FDG-Avid discordant findings. J Nucl Med. 2025;66(1):47\u201353.","journal-title":"J Nucl Med"},{"issue":"10","key":"432_CR16","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad AA, Bressel M, Tan H, et al. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase\u00a02 study. Lancet Oncol. 2024;25(10):1267\u201376.","journal-title":"Lancet Oncol"},{"key":"432_CR17","doi-asserted-by":"publisher","first-page":"S1742","DOI":"10.1016\/j.annonc.2025.09.101","volume":"36","author":"ST Tagawa","year":"2025","unstructured":"Tagawa ST, Sartor O, Piulats JM, et al. Phase\u00a0III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). Ann Oncol. 2025;36:S1742\u20133 (Abstract LBA6).","journal-title":"Ann Oncol"},{"issue":"6","key":"432_CR18","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2967\/jnumed.123.267321","volume":"65","author":"R Seifert","year":"2024","unstructured":"Seifert R, Telli T, Lapa C, et al. Safety and efficacy of extended therapy with [177Lu]Lu-PSMA: a German multicenter study. J Nucl Med. 2024;65(6):909\u201316.","journal-title":"J Nucl Med"},{"issue":"2","key":"432_CR19","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, et al. Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION Trial). Radiology. 2024;312(2):e233460.","journal-title":"Radiology"},{"key":"432_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102862","volume":"77","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Gafita A, de Bono JS, et al. Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase\u00a03 VISION trial. EClinicalMedicine. 2024;77:102862.","journal-title":"EClinicalMedicine"},{"key":"432_CR21","doi-asserted-by":"crossref","unstructured":"Buteau JP, Martin AJ, Emmett L, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase\u00a02 trial. Lancet Oncol. 2022;23(11):1389\u201397.","DOI":"10.1016\/S1470-2045(22)00605-2"},{"key":"432_CR22","doi-asserted-by":"crossref","unstructured":"Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group\u00a03. J Clin Oncol. 2016; 34(12):1402\u201318.","DOI":"10.1200\/JCO.2015.64.2702"},{"issue":"1","key":"432_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.11.008","volume":"6","author":"AL Salner","year":"2020","unstructured":"Salner AL, Blankenship B, Dunnack H, Niemann C, Bertsch H. Lutetium Lu-177 dotatate flare reaction. Adv Radiat Oncol. 2020;6(1):100623.","journal-title":"Adv Radiat Oncol"},{"issue":"12","key":"432_CR24","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","volume":"49","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Fendler WP, et al. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022;49(12):4271\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"432_CR25","doi-asserted-by":"crossref","unstructured":"Emmett L, Subramaniam S, Crumbaker M, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase\u00a02 trial. Lancet Oncol. 2024;25(5):563\u201371.","DOI":"10.1016\/S1470-2045(24)00135-9"},{"issue":"1","key":"432_CR26","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"Gafita A, Djaileb L, Rauscher I, et al. Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer. Radiology. 2023;308(1):e222148.","journal-title":"Radiology"},{"issue":"5","key":"432_CR27","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2967\/jnumed.119.233817","volume":"61","author":"S Fanti","year":"2020","unstructured":"Fanti S, Hadaschik B, Herrmann K. Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET Progression Criteria. J Nucl Med. 2020;61(5):678\u201382.","journal-title":"J Nucl Med"},{"issue":"5","key":"432_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, et al. Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83(5):405\u201312.","journal-title":"Eur Urol"},{"issue":"3","key":"432_CR29","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.122.264677","volume":"64","author":"N John","year":"2023","unstructured":"John N, Pathmanandavel S, Crumbaker M, et al. 177Lu-PSMA SPECT quantitation at 6\u00a0weeks (Dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T Therapy. J Nucl Med. 2023;64(3):410\u20135.","journal-title":"J Nucl Med"},{"issue":"9","key":"432_CR30","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.2967\/jnumed.124.267955","volume":"65","author":"S Yadav","year":"2024","unstructured":"Yadav S, Lowery B, Tuchayi AM, et al. Impact of posttreatment SPECT\/CT on patient management during 177Lu-PSMA-617 radiopharmaceutical therapy. J Nucl Med. 2024;65(9):1395\u2013401.","journal-title":"J Nucl Med"},{"issue":"3","key":"432_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2967\/jnumed.124.268325","volume":"66","author":"L Emmett","year":"2025","unstructured":"Emmett L. SPECT deserves RESPECT: the potential of SPECT\/CT to optimize patient outcomes with theranostics therapy. J Nucl Med. 2025;66(3):349\u201350.","journal-title":"J Nucl Med"},{"key":"432_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","volume":"57","author":"M Crumbaker","year":"2023","unstructured":"Crumbaker M, Goldstein LD, Murray DH, et al. Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with lutetium-177-PSMA-617. Eur Urol Open Sci. 2023;57:30\u20136.","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"432_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13148-025-01811-5","volume":"17","author":"D Amereller","year":"2025","unstructured":"Amereller D, Kramer G, Grubm\u00fcller B, et al. Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [68Ga]Ga-PSMA-11 PET\/CT study. Clin Epigenetics. 2025;17(1):36.","journal-title":"Clin Epigenetics"},{"key":"432_CR34","doi-asserted-by":"crossref","unstructured":"Kwan EM, Ng SWS, Tolmeijer SH, et al. Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase\u00a02 TheraP trial. Nat Med. 2025; 31(8):2722\u201336.","DOI":"10.1038\/s41591-025-03704-9"},{"issue":"11","key":"432_CR35","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/S1470-2045(25)00559-5","volume":"26","author":"L Kostos","year":"2025","unstructured":"Kostos L, Buteau JP, Xie J, et al. Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase\u00a01\/2 trial. Lancet Oncol. 2025;26(11):1479\u201388.","journal-title":"Lancet Oncol"},{"key":"432_CR36","doi-asserted-by":"crossref","unstructured":"Pouget JP, Gabina PM, Herrmann K, et al. EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses. Eur J Nucl Med Mol Imaging. 2025; 52(3):1210\u201322.","DOI":"10.1007\/s00259-024-06963-9"},{"issue":"7","key":"432_CR37","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.7150\/thno.96403","volume":"14","author":"AP Bidkar","year":"2024","unstructured":"Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics. 2024;14(7):2969\u201392.","journal-title":"Theranostics"},{"key":"432_CR38","unstructured":"National Research Council (US) and Institute of Medicine (US) Committee on State of the Science of Nuclear Medicine. Advancing Nuclear Medicine Through Innovation. Washington (DC): National Academies Press (US); 2007. 4, Targeted Radionuclide Therapy. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11464\/. Accessed 7 Jan 2026."},{"issue":"6","key":"432_CR39","doi-asserted-by":"publisher","first-page":"878","DOI":"10.2967\/jnumed.116.186338","volume":"59","author":"S Poty","year":"2018","unstructured":"Poty S, Francesconi LC, McDevitt MR, Morris MJ, Lewis JS. \u03b1-emitters for radiotherapy: from basic radiochemistry to clinical studies-Part 1. J Nucl Med. 2018;59(6):878\u201384.","journal-title":"J Nucl Med"},{"key":"432_CR40","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.nucmedbio.2020.08.004","volume":"92","author":"JL Hatcher-Lamarre","year":"2021","unstructured":"Hatcher-Lamarre JL, Sanders VA, Rahman M, Cutler CS, Francesconi LC. Alpha emitting nuclides for targeted therapy. Nucl Med Biol. 2021;92:228\u201340.","journal-title":"Nucl Med Biol"},{"key":"432_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-3-030-56267-0_4","volume-title":"Locoregional radionuclide cancer therapy","author":"AC Civelek","year":"2021","unstructured":"Civelek AC, Wong FCL. Chapter 4. radionuclide cancer therapy: unsealed alpha- and beta-emitters. In: Wong FCL, editor. Locoregional radionuclide cancer therapy. Cham: Springer Nature Switzerland AG; 2021. p. 61\u201387."},{"key":"432_CR42","doi-asserted-by":"crossref","unstructured":"Sgouros G, Roeske JC, McDevitt MR, et al. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010; 51:311\u201328.","DOI":"10.2967\/jnumed.108.058651"},{"key":"432_CR43","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1158\/1078-0432.CCR-12-0298","volume":"19","author":"KE Baidoo","year":"2013","unstructured":"Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted alpha-particle radiation therapy. Clin Cancer Res. 2013;19:530\u20137.","journal-title":"Clin Cancer Res"},{"key":"432_CR44","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134.","journal-title":"J Nucl Med"},{"issue":"1","key":"432_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ph17010076","volume":"17","author":"M Miederer","year":"2024","unstructured":"Miederer M, Bene\u0161ov\u00e1-Sch\u00e4fer M, Mamat C, et al. Alpha-emitting radionuclides: current status and future perspectives. Pharmaceuticals (Basel). 2024;17(1):76.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"432_CR46","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41585-024-00913-8","volume":"21","author":"RS Eapen","year":"2024","unstructured":"Eapen RS, Williams SG, Macdonald S, et al. Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer. Nat Rev Urol. 2024;21(11):676\u201386.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"432_CR47","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25(2):175\u201383.","journal-title":"Lancet Oncol"},{"key":"432_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.692436","volume":"8","author":"JP Pouget","year":"2021","unstructured":"Pouget JP, Constanzo J. Revisiting the radiobiology of targeted alpha therapy. Front Med. 2021;8:692436.","journal-title":"Front Med"},{"issue":"11","key":"432_CR49","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Starzinski S, de Kouchkovsky I, et al. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase\u00a01 trial. Lancet Oncol. 2023;24(11):1266\u201376.","journal-title":"Lancet Oncol"},{"issue":"5","key":"432_CR50","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.119.234559","volume":"61","author":"C Kratochwil","year":"2020","unstructured":"Kratochwil C, Giesel FL, Heussel CP, et al. Patients resistant against PSMA-targeting \u03b1-radiation therapy often harbor mutations in DNA damage-repair-associated genes. J Nucl Med. 2020;61(5):683\u20138.","journal-title":"J Nucl Med"},{"key":"432_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-020-00130-7","volume":"4","author":"G Recondo","year":"2020","unstructured":"Recondo G, Mahjoubi L, Maillard A, et al. Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. npj Precis Oncol. 2020;4:27.","journal-title":"npj Precis Oncol"},{"issue":"4","key":"432_CR52","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/annonc\/mdv577","volume":"27","author":"G Gebhart","year":"2016","unstructured":"Gebhart G, Lamberts LE, Wimana Z, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol. 2016;27(4):619\u201324.","journal-title":"Ann Oncol"},{"issue":"3","key":"432_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030667","volume":"16","author":"N Andryszak","year":"2024","unstructured":"Andryszak N, \u015awiniuch D, W\u00f3jcik E, Ramlau R, Rucha\u0142a M, Czepczy\u0144ski R. Head-to-head comparison of [18F]PSMA-1007 and [18F]FDG PET\/CT in patients with triple-negative breast cancer. Cancers (Basel). 2024;16(3):667.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"432_CR54","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1097\/RLU.0000000000003005","volume":"45","author":"Q Liu","year":"2020","unstructured":"Liu Q, Zhang J, Kulkarni HR, Baum RP. 177Lu-DOTATOC peptide receptor radionuclide therapy in a patient with neuroendocrine breast carcinoma and breast invasive ductal carcinoma. Clin Nucl Med. 2020;45(5):e232\u20135.","journal-title":"Clin Nucl Med"},{"issue":"9","key":"432_CR55","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/annonc\/mdm058","volume":"18","author":"DB Cornelio","year":"2007","unstructured":"Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol. 2007;18(9):1457\u201366.","journal-title":"Ann Oncol"},{"issue":"9","key":"432_CR56","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.2967\/jnumed.116.188011","volume":"58","author":"C Morgat","year":"2017","unstructured":"Morgat C, MacGrogan G, Brouste V, et al. Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors. J Nucl Med. 2017;58(9):1401\u201317.","journal-title":"J Nucl Med"},{"issue":"8","key":"432_CR57","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2967\/jnumed.120.255679","volume":"62","author":"M D\u2019Huyvetter","year":"2021","unstructured":"D\u2019Huyvetter M, Vos J, Caveliers V, et al. Phase\u00a0I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients. J Nucl Med. 2021;62(8):1097\u2013105.","journal-title":"J Nucl Med"},{"issue":"2","key":"432_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020414","volume":"15","author":"M Li","year":"2023","unstructured":"Li M, Baumhover NJ, Liu D, et al. Preclinical evaluation of a lead specific chelator (PSC) conjugated to radiopeptides for 203Pb and 212Pb-based theranostics. Pharmaceutics. 2023;15(2):414.","journal-title":"Pharmaceutics"},{"issue":"8","key":"432_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26082201","volume":"26","author":"V Liberini","year":"2021","unstructured":"Liberini V, Laudicella R, Capozza M, et al. The future of cancer diagnosis, treatment and surveillance: a systemic review on immunotherapy and immuno-PET radiotracers. Molecules. 2021;26(8):2201.","journal-title":"Molecules"},{"issue":"8","key":"432_CR60","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2967\/jnumed.121.262967","volume":"63","author":"A Bouleau","year":"2022","unstructured":"Bouleau A, Nozach H, Dubois S, et al. Optimizing immuno-PET imaging of tumor PD-L1 expression: Pharmacokinetic, biodistribution, and dosimetric comparisons of 89Zr-labeled anti-PD-L1 antibody formats. J Nucl Med. 2022;63(8):1259\u201365.","journal-title":"J Nucl Med"},{"issue":"8","key":"432_CR61","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","volume":"19","author":"L Bodei","year":"2022","unstructured":"Bodei L, Herrmann K, Sch\u00f6der H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19(8):534\u201350.","journal-title":"Nat Rev Clin Oncol"},{"key":"432_CR62","unstructured":"MEDraysintell. Nuclear Medicine Report & Directory Edition 2022 (Part 1 & 2). 2022. https:\/\/www.medraysintell.com\/_files\/ugd\/1beeab_fd54b6e0a1b9412882d4f038745201b4.pdf. Accessed 7 Jan 2026."},{"key":"432_CR63","unstructured":"IQVIA. Succeeding with innovation: the state of radioligand therapy readiness in Europe. 2023. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/succeeding-with-innovation-state-of-radioligand-therapy). Accessed 7 Jan 2026."},{"issue":"11","key":"432_CR64","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","volume":"25","author":"D Ostwald","year":"2024","unstructured":"Ostwald D, Palta JR, Peristeris P, et al. Radiotherapy and theranostics: a lancet oncology commission. Lancet Oncol. 2024;25(11):e545\u201380.","journal-title":"Lancet Oncol"},{"issue":"4","key":"432_CR65","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/S1470-2045(20)30751-8","volume":"22","author":"H Hricak","year":"2021","unstructured":"Hricak H, Abdel-Wahab M, Atun R, et al. Medical imaging and nuclear medicine: a lancet oncology commission. Lancet Oncol. 2021;22(4):e136\u201372.","journal-title":"Lancet Oncol"},{"key":"432_CR66","unstructured":"IQVIA. Developing efficient patient referral pathways for radioligand therapies: healthcare professional insights from Germany, Italy, France, and China. February 2025. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/developing-efficient-patient-referral-pathways-for-radioligand-therapies. Accessed 7 Jan 2026."}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00432-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00432-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00432-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:03:35Z","timestamp":1782385415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00432-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["432"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00432-z","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,5]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fabrice Andr\u00e9 declares the following: Research grants or advisory boards paid to institution (hospital) from AstraZeneca, Daiichi Sankyo, Lilly, Novartis, BMS, Pfizer, Relay Therapeutics and Roche. Honorarium (self) from Relay Therapeutics, Lilly, AstraZeneca, Novartis and Daiichi Sankyo. Fabrice Barlesi declares the following: Personal financial interests: None. Institutional financial interests: AbbVie, ACEA, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eisai, Eli Lilly Oncology, F. Hoffmann-La Roche Ltd, Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis, Summit Therapeutics and Takeda. Non-financial interests: Principal Investigator for AstraZeneca, Bristol Myers Squibb, Innate Pharma, Merck, Pierre Fabre and F. Hoffmann-La Roche, Ltd, sponsored trials (or ISR). Toni K. Choueiri declares the following: Institutional and\/or personal, paid and\/or unpaid support for research, advisory boards, consultancy, and\/or honoraria past 5\u00a0years, ongoing or not, from: Alkermes, Arcus Bio, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Bicycle Therapeutics, Calithera, Caris, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, HiberCell, IQVA, Infinity, Institut Servier, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan\/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi\/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME and non-CME events (Mashup Media Peerview, OncLive, MJH, CCO, Elite Elements and others), Xencor, outside the submitted work. Institutional patents: filed on molecular alterations and immunotherapy response\/toxicity, rare genitourinary cancers and ctDNA\/liquid biopsies. Equity: Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura Therapeutics, Primium, Abalytics, Faron Pharma Committees: NCCN, GU Steering Committee, ASCO (BOD 6\/2024-), ESMO, ACCRU, and KidneyCan. Medical writing and editorial assistance support for projects other than the current manuscript may have been funded by communications companies in part. Mentored several non-US citizens on research projects with potential funding (in part) from non-US sources\/foreign components. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or\/and royalties potentially involved in research around the subject matter. Supported in part by the Dana-Farber\/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund, and Loker Pinard Funds for Kidney Cancer Research at DFCI. D\u00e9sir\u00e9e Deandreis declares the following: Consultant: ADACAP, GE Healthcare, Spectrum Dynamics, Immedica, Novartis, Telix, Bayer, ITM, AstraZeneca and Lilly. Speaker honoraria: Servier. Financial support: Spectrum Dynamics and Novartis. Karim Fizazi declares the following: Institution: Participation in advisory boards and talks supported by AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Daiichi Sankyo, Johnson and Johnson, Merck\/MSD, Novartis\/AAA, Pfizer, Servier and Vir Oncology. Kevin Haigis declares the following: Research funding: Novartis and TUO Therapeutics. Speaker honoraria: Servier. Heather Jacene declares the following: Research support to institute: Blue Earth Diagnostics, Inc; Lantheus. Consulting: Advanced Accelerator Applications and Spectrum Dynamics. Royalties: Cambridge Publishing. Speaker honoraria: Blue Earth Diagnostics, Inc., Monro and Servier. Patrick Therasse declares the following: Institutional interest: Employed partially by Institut Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The paper is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}